NRx Pharmaceuticals (NASDAQ:NRXP) Raised to “Strong-Buy” at EF Hutton Acquisition Co. I

NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by stock analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued on Monday, Zacks.com reports.

NRXP has been the topic of a number of other research reports. Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 12th. HC Wainwright increased their target price on NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a report on Monday, August 5th.

NRx Pharmaceuticals Price Performance

NRXP stock opened at $1.24 on Monday. The firm has a market cap of $13.27 million, a PE ratio of -0.39 and a beta of 1.25. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The firm has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $2.57.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. As a group, sell-side analysts expect that NRx Pharmaceuticals will post -3.25 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.